Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-05-06
2008-05-06
Fetterolf, Brandon (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S130100, C424S138100, C424S155100, C424S156100
Reexamination Certificate
active
07368428
ABSTRACT:
Methods and compositions for restoring sensitivity to the antitumorigenic effects of antiestrogen therapy and/or cytotoxic therapy and inducing cell apoptosis are provided. Contacting tumor cells to GP88 antagonists (e.g., anti-GP88 antibodies, anti-GP88 antisense nucleic acids, GP88 siRNA, and small molecules) induces apoptosis and restores sensitivity to the antitumorigenic effects of antiestrogen therapy and cytotoxic therapy.
REFERENCES:
patent: 5416192 (1995-05-01), Shoyab et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 6309826 (2001-10-01), Serrero
patent: 6511986 (2003-01-01), Zhang et al.
patent: 6558668 (2003-05-01), Liau
patent: 6570002 (2003-05-01), Hardwick et al.
patent: 6586395 (2003-07-01), Kiefer et al.
patent: 2002/0025543 (2002-02-01), Serrero
patent: 2005/0175616 (2005-08-01), Kiener et al.
patent: WO 91 15510 (1991-10-01), None
Lu et al. Biochem. Biophys, Research Comm. 1999; 256: 204-207.
Markert et al. Physiol Genomics 2001; 5: 21-33.
Wang et al. Clinical Cancer Research 2003; 9: 2221.
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Slamon et al. (Science vol. 235, Jan. 1987, pp. 177-182).
International Search Report dated Aug. 31, 2005.
Serrero, G. et al.,Effect of Testosterone on the Growth Properties and on Epidermal Growth Factor Receptor Expression in the Teratoma-derived Tumorigenic Cell Line 1246-3A,Cancer Research 52, 1992, pp. 4242-4247.
Alberts, B., et al.,Molecular Biology of the Cell,Garland Publishing, Inc., 1983.
Cross, M. et al.,Growth Factors in Development, Transformation, and Tumorigenesis,Cell, vol. 64, 1991, pp. 271-280.
Sporn, M.B. et al.,Autocrine Secretion and Malignant Transformation of Cells,The New England Journal of Medicine, vol. 303, 1980, pp. 878-880.
Zhou, J. et al.,Purification of an Autocrine Growth Factor Homologous with Mouse Epithelin Precursor from a Highly Tumorigenic Cell Line,The Journal of Biological Chemistry, vol. 268, No. 15, 1993, pp. 10863-10869.
Plowman, G. et al.,The Epithelin Precursor Encodes Two Proteins with Opposing Activities on Epithelial Cell Growth,The Journal of Biological Chemistry, vol. 267, No. 18, 1992, pp. 13073-13078.
Bateman, A. et al.,Granulins, a Novel Class of Peptide from Leukocytes,Biochemical and Biophysical Research Communications, vol. 173, No. 3, 1990, pp. 1161-1168.
Nestor, J. et al.,A Synthetic Fragment of Rat Transforming Growth Factor with Receptor Binding and Antigenic Properties,Biochemical and Biophysical Research Communications, vol. 129, No. 1, 1985, pp. 226-232.
Adelman, J. et al.,In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone,DNA, vol. 2, No. 3, 1983, pp. 183-193.
Serrero, G. et al.,An In Vitro Model to Study Adipose Differentiation in Serum-Free Medium,Analytical Biochemistry 120, 1982, pp. 351-359.
Serrero-Dave, G.,Study of a Teratoma-Derived Adipogenic Cell Line 1246 and Isolation of an Insulin-Independent Variant in Serum-Free Medium,Cancer Center, University of California, pp. 366-376, 1996.
Serrero, G.,Tumorigenicity Associated with Loss of Differentiation and of Response to Insulin in the Adipogenic Cell Line 1246,In Vitro Cellular & Developmental Biology, vol. 21, No. 9, 1985, pp. 537-540.
Serrero, G. et al.,Decreased Transforming Growth Factor-β Response and Binding in Insulin-independent Teratoma-Derived Cell Lines with Increased Tumorigenic Properties,Journal of Cellular Physiology, 149, 1991, pp. 503-511.
Arteaga, C. et al.,Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antibody against the Type I Somatomedin Receptor,Cancer Research 49, 1989, pp. 6237-6241.
Schofield, P. et al.,The Biological Effects of a High Molecular Weight Form of IGF II in a Pluripotential Human Teratocarcinoma Cell Line,Anticancer Research 14, 1994, pp. 533-538.
Trojan, J. et al.,Gene therapy of murine teratocarcinoma: Separate functions for insulin-like growth factors I and II in immunogenicity and differentiation,Proc. Natl. Acad. Sci. USA, vol. 91, 1994, pp. 6088-6092.
Trojan, J. et al.,Treatment and Prevention of Rat Glioblastoma by Immunogenic C6 Cells Expressing Antisense Insulin-Like Growth Factor I RNA,Science, vol. 259, 1993, pp. 94-96.
Kohler, G. et al.,Continuous cultures of fused cells secreting antibody of predefined specificity,Nature, vol. 256, 1975, pp. 495-497.
de St. Groth, S.F. et al.,Production of Monoclonal Antibodies: Strategy and Tactics,Journal of Immunology Methods, 35, 1980, pp. 1-21.
Schreier, M. et al.,Hybridoma Techniques,Cold Spring Harbor Laboratory, 1980.
Cabilly, S. et al.,Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli,Proc. Natl. Acad. Sci. USA, vol. 81, 1984, pp. 3273-3277.
Morrison, S. et al.,Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains,Proc. Natl. Acad. Sci. USA, vol. 81, 1984, pp. 6851-6855.
Liu, A. et al.,Chimeric mouse-human lgG1 antibody that can mediate lysis of cancer cells,Proc. Natl. Acad. Sci. USA, vol. 84, 1987, pp. 3439-3443.
Better, M. et al.,Escherichia coli Secretion of an Active Chimeric Antibody Fragment,Science, vol. 240, 1988, pp. 1041-1043.
Riechmann, L. et al.,Reshaping human antibodies for therapy,Nature, vol. 332, 1988, pp. 323-327.
Baca, M. et al.,Antibody Humanization Using Monovalent Phage Display,J. Biol. Chem., vol. 272, No. 16, 1997, pp. 10678-10684.
Rosok, M.J. et al.,A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab,J. Biol. Chem., vol. 271, No. 37, 1996, pp. 22611-22618.
Wahl, R.L. et al.,Improved Radioimaging and Tumor Localization with Monoclonal F(ab'), The Journal of Nuclear Medicine, vol. 24, No. 4, 1983, pp. 316-325.
Mulshine, J.L.,Clinical Use of a Monoclonal Antibody to Bombesin-lik Peptide in Patients with Lung Cancer,Annals New York Academy of Sciences, pp. 360-372, 1996.
Munroe, S.H.,Antisense RNA inhibits splicing of pre-mRNA in vitro,The EMBO Journal, vol. 7, No. 8, 1988, pp. 2523-2532.
Mulis, K.B. et al.,Specific Synthesis of DNA in Vitro via a Polymerase-Catalyzed Chain Reaction,Methods in Enzymology, vol. 155, 1987, pp. 335-350.
Mercola, D. et al.,Antisense approaches to cancer gene therapy,Cancer Gene Therapy, vol. 2, No. 1, 1995, pp. 47-59.
Wagner, R. W.,Gene inhibition using antisense oligodeoxynucleotides,Nature, vol. 372, 1994, pp. 333-335.
Maniatis, T. et al.,Molecular Cloning: A Laboratory Manual,Cold Spring Harbor Laboratory, 1982.
Brysch, W. et al.,Design and Application of Antisense Oligonucleotides in Cell Culture, in Vivo, and as Therapeutic Agents,Cellular and Molecular Neurobiology, vol. 14, No. 5, 1994, pp. 557-568.
Helene, C.,Rational Design of Sequence-specific Oncogene Inhibitors Based on Antisense and Antigene Oligonucleotides,Eur. J. Cancer, vol. 27, No. 11, 1991, pp. 1466-1471.
Giles, R.V. et al.,Optimization of Antisense Oligodeoxynucleotide Structure for Targeting ber-abl* mRNA,Blood, vol. 86, No. 2, 1995, pp. 744-754.
Thaler, D.S. et al.,Extending the chemistry that supports genetic information transfer in vivo: Phosphorothioate DNA, phosphorothioate RNA, 2′-O-methyl RNA, and methylphosphonate DNA,Proc. Natl. Acad. Sci. USA, vol. 93, 1996, pp. 1352-1356.
Gryaznov, S. et al.,Oligonucleotide N3′-P5′ phosphoramidates as antisense agents,Nucleic Acids Research, vol. 24, No. 8, 1996, pp. 1508-1514.
Lappalainen, K. et al.,Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells,Biochimica et Biophysica Acta 1196, 1994, pp. 201-208.
Ensoli, B. et al.,Block of AIDS-Kaposi's Sarcoma(KS)Cell Growth, Angiogenesis, and Lesion Formation in Nude Mice by Antisense Oligonucleotide Targeting Basic Fibroblast Growth Factor,The Journal of Clinical Investigation, Inc., vol. 94, 1994, pp. 1736-1746.
Peng, B. et al.,Growth Inhibition of Malignant CD5+B(B-1)Cells by Antisense IL-10 Oligonucleotide,Leukemia Research, vol. 19, No. 3, 1995, pp. 159-167.
Donovan, R.S. et al.,Review: Optimizing inducer and culture conditions for expression of foreign proteins under the control of t
A&G Pharmaceutical, Inc.
Dickstein & Shapiro LLP
Fetterolf Brandon
LandOfFree
Compositions and methods for restoring sensitivity of tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for restoring sensitivity of tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for restoring sensitivity of tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2815206